MNPR falls as seller pressure persists

Traders Union
All News
Stocks
Monopar Therapeutics drops 3.93% today

Highlights

MNPR/USD remains under sustained selling pressure with price trading below short-, medium-, and long-term moving averages.
Momentum indicators send mixed signals as some show bullish interest but intraday oscillators diverge, adding uncertainty.
Expected range over the next 2 to 3 trading days is $68.5982 to $74.0318, with a 76% probability of further downside.

Bullish intraday signals amid resistance and trend uncertainty

On the technical front, MNPR/USD trades below its MA-20 and MA-50 on the hourly chart, and continues to hold under the MA-200 on the daily timeframe. The Ichimoku Kijun level at $71.8025 sets immediate resistance for upward moves. Key indicators show mixed momentum: MACD and ADX highlight buying interest, with reinforcement from RSI (Buy), CCI (Buy), and positive Bull/Bear Power—signaling buyers are active in intraday periods. Contrasting this, the Stochastic RSI stands at Strong Sell while the Awesome Oscillator reads Neutral, revealing an internal divergence and uncertainty in trend momentum.

Downside bias prevails as risk skews toward support break

Over the next 2 to 3 trading days, MNPR/USD is expected to trade within a range of $68.5982 to $74.0318. Statistical probabilities suggest a 24% chance of an upward move versus a 76% likelihood of further declines. The baseline scenario envisions price oscillation within this corridor, with a bullish breakout possible if the immediate resistance is reclaimed and a bearish scenario unfolding if support at the lower boundary fails.

Anton Kharitonov, expert at Traders Union, notes that Monopar Therapeutics is showing a technically weak profile with price below all key moving averages and momentum indicators divided. He sees a cautious environment, given strong intraday buying signals but overall trend uncertainty and no supportive news catalysts. Until the price reclaims resistance at $71.8025, Kharitonov expects sideways-to-lower movement to dominate. "Base case remains range trading with a bearish tilt unless the upper boundary is recovered — any upside here is not yet convincing."

In a recent review, Monopar Therapeutics stock was seen consolidating with a slightly bullish tilt amid mixed technical signals and indecision among traders. The current analysis broadens that perspective by highlighting an increased risk of further declines in the near term, making sustained support above the $68.60 level a critical threshold for any potential reversal.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.